Details

Autor(en) / Beteiligte

• Kovvuru, Sukanthi
• Nalleballe, Krishna
• Onteddu, Sanjeeva Reddy
• Sharma, Rohan
• Jasti, Madhu
• Kapoor, Nidhi
• Veerapaneni, Karthika
• Yadala, Sisira
• Dandu, Vasuki
• Archer, Robert
• Nowak, Richard J.
• Roy, Bhaskar

Titel

Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic

Ist Teil von

• Journal of the neurological sciences, 2021-01, Vol.420, p.117230-117230, Article 117230

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2021

Link zum Volltext

Quelle

ScienceDirect

Beschreibungen/Notizen

• To study the risk of acquiring Corona Virus Disease 2019 (COVID-19) and its outcomes in patients on immunosuppressive therapy (IST) for chronic autoimmune neuromuscular disorders (aNMD) and multiple sclerosis (MS). We used TriNetX, a global health collaborative clinical research platform collecting real-time electronic medical records data, which has one of the largest known global COVID-19 database. We included patients with chronic autoimmune neuromuscular disorders (aNMD) [myasthenia gravis (MG), inflammatory myositis, and chronic inflammatory neuropathies (CIN)] and MS, based on the International Classification of Disease-10 (ICD-10) coding for one year before January 20th, 2020. We examined the use of IST, rate of COVID- 19, hospitalization, intubation, and mortality among the patients with aNMD and MS. A total of 33,451 patients with aNMD and 42,899 patients with MS were included. Among them, 111 (0.33%) patients with aNMD and 115 patients (0.27%) with MS had COVID-19. About one third of them required hospitalization. IST did not appear to have a significant impact on overall infection risk in either group; however, risk of hospitalization for immunosuppressed patients with aNMD was higher (Odds ratio 2.86, p-value 0.011). IST use does not appear to make patients with aNMD and MS more vulnerable to COVID-19. IST may be continued during the pandemic, as previously suggested by expert opinion guidelines. However, it is important to consider individualizing immunotherapy regimens in some cases. Additional physician reported registry-based data is needed to further confirm these findings. •Majority of patients with chronic autoimmune neurological disorders(cAND’s) likely have mild-to-moderate COVID-19.•Patients with cAND’s who had COVID-19, 33% were hospitalized 12.1% required intensive care unit stay and 8.5% died.•Immunosuppressive therapies did not appear to have a significant impact on overall infection risk.